Immunotherapy, which is harnessed by neutralizing antibodies to checkpoint entities such as PD-1 and its ligand PD-L1, has been successful for various cancers; however, limited efficacy has been observed in pancreatic cancer [10,11] and also for anti-CTLA-4 [12]. The gene discussed is CD274; the disease is pancreatic neoplasm.